161 related articles for article (PubMed ID: 30652228)
21. Tranilast and cisplatin as an experimental combination therapy for scirrhous gastric cancer.
Murahashi K; Yashiro M; Inoue T; Nishimura S; Matsuoka T; Sawada T; Sowa M; Hirakawa-Ys Chung K
Int J Oncol; 1998 Dec; 13(6):1235-40. PubMed ID: 9824637
[TBL] [Abstract][Full Text] [Related]
22. A novel molecular targeting compound as K-samII/FGF-R2 phosphorylation inhibitor, Ki23057, for Scirrhous gastric cancer.
Nakamura K; Yashiro M; Matsuoka T; Tendo M; Shimizu T; Miwa A; Hirakawa K
Gastroenterology; 2006 Nov; 131(5):1530-41. PubMed ID: 17101326
[TBL] [Abstract][Full Text] [Related]
23. Identification of candidates for driver oncogenes in scirrhous-type gastric cancer cell lines.
Sai E; Miwa Y; Takeyama R; Kojima S; Ueno T; Yashiro M; Seto Y; Mano H
Cancer Sci; 2019 Aug; 110(8):2643-2651. PubMed ID: 31222839
[TBL] [Abstract][Full Text] [Related]
24. A FGFR2 inhibitor, Ki23057, enhances the chemosensitivity of drug-resistant gastric cancer cells.
Qiu H; Yashiro M; Zhang X; Miwa A; Hirakawa K
Cancer Lett; 2011 Aug; 307(1):47-52. PubMed ID: 21482024
[TBL] [Abstract][Full Text] [Related]
25. Multiple receptor tyrosine kinase activation attenuates therapeutic efficacy of the fibroblast growth factor receptor 2 inhibitor AZD4547 in FGFR2 amplified gastric cancer.
Chang J; Wang S; Zhang Z; Liu X; Wu Z; Geng R; Ge X; Dai C; Liu R; Zhang Q; Li W; Li J
Oncotarget; 2015 Feb; 6(4):2009-22. PubMed ID: 25576915
[TBL] [Abstract][Full Text] [Related]
26. Inhibitory effect of a selective cyclooxygenase inhibitor on the invasion-stimulating activity of orthotopic fibroblasts for scirrhous gastric cancer cells.
Tendo M; Yashiro M; Nakazawa K; Yamada N; Hirakawa K
Cancer Sci; 2005 Jul; 96(7):451-5. PubMed ID: 16053517
[TBL] [Abstract][Full Text] [Related]
27. Tranilast (N-(3,4-dimethoxycinnamoyl) anthranilic acid) down-regulates the growth of scirrhous gastric cancer.
Yashiro M; Chung YS; Sowa M
Anticancer Res; 1997; 17(2A):895-900. PubMed ID: 9137424
[TBL] [Abstract][Full Text] [Related]
28. Selective cyclooxygenase-2 inhibitor downregulates the paracrine epithelial-mesenchymal interactions of growth in scirrhous gastric carcinoma.
Yashiro M; Nakazawa K; Tendo M; Kosaka K; Shinto O; Hirakawa K
Int J Cancer; 2007 Feb; 120(3):686-93. PubMed ID: 17096355
[TBL] [Abstract][Full Text] [Related]
29. [Mechanisms responsible for the progression of scirrhous gastric cancer].
Yashiro M; Ohira M; Muguruma K; Shinto O; Hirakawa K
Nihon Rinsho; 2012 Oct; 70(10):1812-6. PubMed ID: 23198567
[TBL] [Abstract][Full Text] [Related]
30. A reciprocal regulatory circuit between CD44 and FGFR2 via c-myc controls gastric cancer cell growth.
Park J; Kim SY; Kim HJ; Kim KM; Choi EY; Kang MS
Oncotarget; 2016 May; 7(19):28670-83. PubMed ID: 27107424
[TBL] [Abstract][Full Text] [Related]
31. Novel models for human scirrhous gastric carcinoma in vivo.
Takemura S; Yashiro M; Sunami T; Tendo M; Hirakawa K
Cancer Sci; 2004 Nov; 95(11):893-900. PubMed ID: 15546507
[TBL] [Abstract][Full Text] [Related]
32. PI3K/Akt signalling is required for the attachment and spreading, and growth in vivo of metastatic scirrhous gastric carcinoma.
Matsuoka T; Yashiro M; Nishioka N; Hirakawa K; Olden K; Roberts JD
Br J Cancer; 2012 Apr; 106(9):1535-42. PubMed ID: 22531720
[TBL] [Abstract][Full Text] [Related]
33. Twist1 correlates with poor differentiation and progression in gastric adenocarcinoma via elevation of FGFR2 expression.
Zhu DY; Guo QS; Li YL; Cui B; Guo J; Liu JX; Li P
World J Gastroenterol; 2014 Dec; 20(48):18306-15. PubMed ID: 25561797
[TBL] [Abstract][Full Text] [Related]
34. FGF18-FGFR2 signaling triggers the activation of c-Jun-YAP1 axis to promote carcinogenesis in a subgroup of gastric cancer patients and indicates translational potential.
Zhang J; Wong CC; Leung KT; Wu F; Zhou Y; Tong JHM; Chan RCK; Li H; Wang Y; Yan H; Liu L; Wu WKK; Chan MWY; Cheng ASL; Yu J; Wong N; Lo KW; To KF; Kang W
Oncogene; 2020 Oct; 39(43):6647-6663. PubMed ID: 32934314
[TBL] [Abstract][Full Text] [Related]
35. miR‑494 inhibits cancer‑initiating cell phenotypes and reverses resistance to lapatinib by downregulating FGFR2 in HER2‑positive gastric cancer.
Yu Y; Yu X; Liu H; Song Q; Yang Y
Int J Mol Med; 2018 Aug; 42(2):998-1007. PubMed ID: 29786108
[TBL] [Abstract][Full Text] [Related]
36. Antitumor Effects and Mechanisms of AZD4547 on FGFR2-Deregulated Endometrial Cancer Cells.
Kwak Y; Cho H; Hur W; Sim T
Mol Cancer Ther; 2015 Oct; 14(10):2292-302. PubMed ID: 26294741
[TBL] [Abstract][Full Text] [Related]
37. Laparoscopic-assisted intraperitoneal chemotherapy for patients with scirrhous gastric cancer.
Ikeguchi M; Matsumoto S; Yoshioka S; Murakami D; Kanaji S; Ohro S; Yamaguchi K; Saito H; Tatebe S; Kondo A; Tsujitani S; Kaibara N
Chemotherapy; 2005 Mar; 51(1):15-20. PubMed ID: 15722628
[TBL] [Abstract][Full Text] [Related]
38. Preclinical study of a "tailor-made" combination of NK4-expressing gene therapy and gefitinib (ZD1839, Iressa) for disseminated peritoneal scirrhous gastric cancer.
Namiki Y; Namiki T; Yoshida H; Date M; Yashiro M; Matsumoto K; Nakamura T; Yanagihara K; Tada N; Satoi J; Fujise K
Int J Cancer; 2006 Mar; 118(6):1545-55. PubMed ID: 16206271
[TBL] [Abstract][Full Text] [Related]
39. Role of alpha 2 beta 1- and alpha 3 beta 1-integrin in the peritoneal implantation of scirrhous gastric carcinoma.
Nishimura S; Chung YS; Yashiro M; Inoue T; Sowa M
Br J Cancer; 1996 Nov; 74(9):1406-12. PubMed ID: 8912536
[TBL] [Abstract][Full Text] [Related]
40. Epigenetic modulation and repression of miR-200b by cancer-associated fibroblasts contribute to cancer invasion and peritoneal dissemination in gastric cancer.
Kurashige J; Mima K; Sawada G; Takahashi Y; Eguchi H; Sugimachi K; Mori M; Yanagihara K; Yashiro M; Hirakawa K; Baba H; Mimori K
Carcinogenesis; 2015 Jan; 36(1):133-41. PubMed ID: 25411357
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
